By: 4titudinous
19 Feb 2004, 08:46 AM EST
Msg. 139221 of 139233
Jump to msg. #  
Patent application NEWS re: AVR118/Product R & leukemia:
- - - - -
View Replies »



By: FoxChase1803
19 Feb 2004, 08:55 AM EST
Msg. 139222 of 139233
(This msg. is a reply to 139221 by 4titudinous.)
Jump to msg. #  
4titudinous: Incredible:

[0016] Product R has been found to be effective in the treatment of cancers emanating from lymphocytic cells including patients with acute lymphocytic leukemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma.

[0017] According to the present invention, Product R is preferably administered to the patient parenterally, while other administration routes such as nasal spray or ingestion may also be employed. A suitable effective dose of Product R will be in the range of from about 5 microliters to about 40 microliters per kilogram of body weight per day, preferably in the range of about 10 microliters to about 25 microliters per kilogram of body weight per day. Most preferably Product R is administered in an amount of about 30 microliters per kilogram of body weight per day for about one week, followed by about 15 microliters per kilogram of body weight per day in a sterile injectable formulation. The desired dose may be administered as two, three or more sub-doses at appropriate intervals, generally equally spread in time, throughout the day. Preferably, the full daily dose is administered in one administration.

[0018] Alternatively, Product R may be administered to the patients according to the conventional dosages or any dosages that are apparent to a person of ordinary skill in the art.

[0019] Product R may be administered by any suitable injection route including, but not limited to intravenously, intraperitoneally, subcutaneously, intramuscularly, and intradermally, etc. The presently preferred route of administration is intramuscularly. It will be appreciated that the preferred route may vary with, for example, the condition and age of the recipient.

[0020] Product R may be used in therapy in conjunction with other medicaments including corticosteroid, gamma globulin, glucose, or vitamins, antiviral agents such as interferon or interleukin, etc.

[0021] The present invention is further provide a method for treating patients suffering from non-solid tumors such as Lymphocytic Leukemias, Hodgkin's Disease and Non/Hodgkin's Lymphoma by administering the active components or active portion(s) of Product R to such patients. The active components or portions of Product R are described in the above mentioned U.S. Pat. Nos. 6,303,153 and 6,528,098.

[0022] While it is possible for Product R to be administered as part of a pharmaceutical formulation, it is preferable to present it alone, although it may be administered at about the same time as one or more other pharmaceuticals are independently administered. If Product R is administered as part of a pharmaceutical formulation, the formulations of the present invention comprise at least one administered ingredient, i.e. Product R, as above defined, together with one or more acceptable carriers thereof and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

By: SUE32073
19 Feb 2004, 09:01 AM EST
Msg. 139224 of 139234
Jump to msg. #  
Bummer!!! Survives the disease but a fall kills him!!


[0027] In a 71 year old white male with acute lymphocytic leukemia who failed intensive courses of conventional chemotherapy, Product R was effective in keeping this patient alive for 18 months. Chemotherapy was discontinued soon after commencing Product R therapy. Indeed, after commencing Product R therapy the patient's bone marrow which had contained 30% blast cells lost these blast cells. In addition, blast cells disappeared from the peripheral blood. During this two year period the patient put on weight, had a normal appetite, claimed that he felt well, and was able to live a normal quality of life. The patient died soon after a fall in his home.
By: FoxChase1803
19 Feb 2004, 10:00 AM EST
Msg. 139237 of 139241
(This msg. is a reply to 139231 by 4titudinous.)
Jump to msg. #  
4titudinous: All these patent applications are so very important. I have my eye on this one also. I believe it's still in the application mode:

United States Patent Application 20010006682
Kind Code A1


"[0007] Cancer patients often exhibit a suppressed immune response. This immunosuppression is most likely caused by agents used to treat the cancer as well as by factors secreted by the cancer cells themselves. Most anti-cancer agents, such a radiation therapy and chemotherapy, inadvertently destroy lymphocytes and other cells important to the immune system. Some tumors, such as the tumors in Hodgkin's disease, release or induce the release of immunosuppressive factors. Hodgkin's disease patients exhibit an abnormally high sensitivity to intracellular parasitic infections such as tuberculosis and herpes virus infections.

[0008] Viruses have developed several ways of suppressing the host immune response. Some viruses, such as HIV, target at the host immune system, resulting in a complete destruction of the system. In general, viruses can invade and suppress the host system by infecting T or B cells and abrogate their function, or infecting the thymus and inducing tolerance, or destroying speciallized antigen-presenting cells."

By: FoxChase1803
19 Feb 2004, 10:08 AM EST
Msg. 139238 of 139241
(This msg. is a reply to 139236 by lunker10706.)
Jump to msg. #  
Larry, Patent Application:

By: 4titudinous
19 Feb 2004, 08:46 AM EST
Msg. 139221 of 139237

Patent application NEWS re: AVR118/Product R & leukemia:
By: FoxChase1803
19 Feb 2004, 10:10 AM EST
Msg. 139239 of 139241
Jump to msg. #  

Dr. James D'Olimpio, Spokesman-at-large for ADVR is to present a paper entitled «Use of a Peptide Nucleic Acid in Cancer Regulation and Metastasis: A Preliminary Report of Bimodal Effects in Vitro». The paper is to be presented at the 1st ISC Conference on Cancer Chemotherapeutics-Molecular Targets, Pharmacology and Clinical Applications, which will take place in Florence, Italy from February 19-21, 2004. The conference is meant to provide a forum for the dissemination of the latest knowledge in the field of anticancer drug research and development, and is jointly sponsored by the International Society of Chemotherapy and the Societ Italiana di Chemioterapia. Dr. DOlimpio will be presenting the results of scientific research spearheaded and conducted by the companys scientists, Dr. Maribel deDiego and Dr. Sharon Malia on the effects of AVR118 against tumor cell lines in vitro.


International Society  of Chemotherapy

1st International Conference 

on Cancer Therapeutics


Societą Italiana di Chemioterapia


Molecular Targets, Pharmacology

and Clinical Applications


February 19-21, 2004
Palazzo dei Congressi, Firenze, Italy